Atherosclerotic Cardiovascular Disease (ASCVD) Risk

ASCVD Risk Estimation Calculator:

http://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/ (Accessed 2018)

Other Potential Scoring Systems for Cardiovascular Risk

Scoring System	Notes on Scoring System	Calculator or Additional Information Available
Framingham	Intended for use in nondiabetic patients 30–79 years old with no history of coronary heart disease or intermittent claudication Most widely applicable to patients without previous cardiac disease	https://www.framinghamheartstudy. org/fhs-risk-functions/cardiovascular- disease-10-year-risk/
Multi-Ethnic Study of Atherosclerosis (MESA)	Most appropriate for patients 45–85 years old and in the following racial/ethnic groups: Caucasian, Chinese American, African American, or Hispanic	https://mesa-nhlbi.org/MESACHDRisk/ MesaRiskScore/RiskScore.aspx
Reynolds Risk Score for Cardiovascular Risk	• For women > 45 years old	http://www.reynoldsriskscore.org
UK Prospective Diabetes Study (UKPDS) Risk	Scoring system for type 2 diabetes	https://www.dtu.ox.ac.uk/riskengine/

Note: All websites accessed 2018.

Risk Factors for Atherosclerotic Cardiovascular Disease

Major Risk Factors	Other (Additional or Nontraditional)
↑ Age ↑ Serum cholesterol ↑ Non-HDL ↑ LDL-C Low HDL-C Diabetes mellitus Hypertension Chronic kidney disease Cigarette smoking Family history of ASCVD	Obesity/abdominal obesity Family history of hyperlipidemia ↑ small, dense LDL-C ↑ Apo-lipoprotein B ↑ LDL particle concentration Fasting/postprandial hypertriglyeridemia PCOS Dyslipidemic triad* ↑ Lipoprotein (a) ↑ Clotting factors ↑ Inflammatory markers (hsCRP; Lp-PLA,)

Notes: HDL = high-density lipoprotein; LDL = low-density lipoprotein; C = cholesterol; ASCVD = atherosclerotic cardiovascular disease; PCOS = polycystic ovarian syndrome; hsCRP = high sensitive C-reactive protein; Lp-PLA₂ = lipoprotein-associated phospholipase. * = hypertriglyceridemia (triglycerides >150 mg/dL); low high-density lipoprotein cholesterol (HDL-C; \leq 35 mg/dL); and small, dense low-density lipoprotein particles.

Reference: Modified from Table 6 — Clinical Practice Guidelines for Managing Dyslidemia & Prevention of CVD, Endocr Pract. 2017;23(Suppl 2) 17 Copyright © 2017 AACE.